as on February 18, 2026 at 6:11 am IST
Day's Low
Day's High
1.32%
Downside
18.77%
Upside
52 Week's Low
52 Week's High
74.25%
Downside
55.23%
Upside
Check Kalaris Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$161.8M
EPS (TTM)
-3.6967
Dividend Yield
0.00%
PE Ratio (TTM)
0PEG Ratio
0Return On Equity TTM
0.00%
Compare market cap, revenue, PE, and other key metrics of Kalaris Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| NA | $161.8M | NA | NA | 0.00% | |
| BUY | $126.0B | 128.75% | 32.06 | 32.94% | |
| NA | $38.3B | NA | 665.52 | 1.38% | |
| BUY | $41.7B | 100.86% | 134.94 | 8.45% | |
| BUY | $84.9B | 66.74% | 19.38 | 31.41% |
Search interest for Kalaris Therapeutics Inc Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
![]()
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 49.1% return, outperforming this stock by 143.7%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 49.9% return, outperforming this stock by 62.5%
Price Dip
![]()
In the last 7 days, KLRS stock has moved down by -13.7%
| Organisation | Kalaris Therapeutics Inc |
| Headquarters | 628 Middlefield Road, Palo Alto, CA, United States, 94301 |
| CEO | Mr. Andrew Oxtoby |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder |
Mr. Brett R. Hagen | Chief Accounting Officer |
Dr. Matthew Feinsod M.D. | Chief Medical Officer |
Ms. Kristine Curtiss | Senior Vice President of Clinical |
Mr. Andrew Oxtoby | President, CEO & Director |
Dr. Michael Philip Dybbs Ph.D. | Director & Co-Founder |
Mr. Matthew Gall M.B.A. | CFO & Treasurer |
Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC |
Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder |
Kalaris Therapeutics Inc share price today is $8.31 as on . Kalaris Therapeutics Inc share today touched a day high of $9.87 and a low of $8.2.
Kalaris Therapeutics Inc share touched a 52 week high of $12.9 on and a 52 week low of $2.14 on . Kalaris Therapeutics Inc stock price today i.e. is trending at $8.31,which is 35.58% down from its 52 week high and 288.32% up from its 52 week low.
Kalaris Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Kalaris Therapeutics Inc (KLRS) shares with as little as ₹90.652 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹906.52 in Kalaris Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Kalaris Therapeutics Inc share’s latest price of $8.31 as on February 18, 2026 at 12:41 am IST, you will get 1.2034 shares of Kalaris Therapeutics Inc. Learn more about
fractional shares .